Enhanced Combination Therapy for Infection Treatment and Prevention

An improved combination therapy for treating and preventing infections, comprising an antibiotic and/or anti-viral drug combination followed by a vaccine directed to a causative agent of the infection, which induces an immune response against multiple strains of the causative agent and prevents in vivo mutations.

The original patent disclosed methods for treating, ameliorating, or preventing infections using a combination of antibiotics, anti-viral drugs, and vaccines. However, these methods had limitations, such as the risk of vaccine breakthrough infections and in vivo mutations of the causative agent. The new inventive concept addresses these limitations by introducing a system and method for preventing vaccine breakthrough infections and in vivo mutations, thereby enhancing the efficacy and safety of infection treatment and prevention.

The enhanced combination therapy comprises administering an antibiotic and/or anti-viral drug combination to a subject in need thereof, followed by administering a vaccine directed to a causative agent of the infection. The vaccine is formulated to induce an immune response against multiple strains of the causative agent, and the antibiotic and/or anti-viral drug combination is dosed to prevent in vivo mutations of the causative agent. This approach ensures a more comprehensive and durable immune response, reducing the risk of vaccine breakthrough infections and in vivo mutations.

The new claims introduce the concept of preventing in vivo mutations of the causative agent through the use of an antibiotic and/or anti-viral drug combination, which is a novel and non-obvious improvement over the original patent. Additionally, the use of a vaccine formulated to induce an immune response against multiple strains of the causative agent provides a broader and more effective immune response.

Alternative embodiments of the inventive concept may include varying the sequence of administration, the dosage and formulation of the antibiotic and/or anti-viral drug combination, and the type and strain of the causative agent targeted by the vaccine. Additionally, the inventive concept could be adapted for use in different populations, such as pediatric or geriatric populations, or for treating different types of infections.

The enhanced combination therapy has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of infectious disease treatment and prevention. The market for infection treatment and prevention is substantial, with a growing need for effective and safe therapies. The inventive concept's ability to prevent vaccine breakthrough infections and in vivo mutations makes it an attractive solution for pharmaceutical companies, healthcare providers, and patients.